U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07071155) titled 'Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia' on July 09.
Brief Summary: This research is being done to evaluate effectiveness, safety, and tolerability of a study drug called momelotinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) or chronic neutrophilic leukemia (CNL), in addition to standard treatment which usually includes a hypomethylating agent like azacitidine or decitabine. Treatment options for this diagnosis remain limited and investigators need better treatments to he...